Publications by authors named "M R Bending"
Aims: The study objective was to develop an open-source replicate of a cost-effectiveness model developed by National Institute for Health and Care (NICE), in order to explore uncertainties in health economic modeling of novel pharmacological neuropathic pain treatments.
Materials And Methods: The NICE model, consisting of a decision tree with branches for discrete levels of pain relief and adverse event (AE) severities, was replicated using R, and used to compare a hypothetical neuropathic pain drug to pregabalin. Model parameters were sourced from NICE's clinical guidelines and associated with probability distributions to account for underlying uncertainty.
Article Synopsis
- Multiple sclerosis (MS) is a chronic autoimmune disease with relapsing-remitting forms (RRMS) affecting ~85% of patients, and this study focuses on the effectiveness of fingolimod compared to other disease-modifying therapies (DMTs) for treating highly active (HA) and rapidly evolving severe (RES) RRMS.
- A systematic literature review and Bayesian network meta-analysis were conducted, identifying a limited number of studies that compared fingolimod with other DMTs like dimethyl fumarate (DMF) and natalizumab, focusing on annualized relapse rates and disability progression.
- The findings suggested a favorable trend for fingolimod over DMF in HA RRMS, but results for RES RRMS
Background: The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.
View Article and Find Full Text PDFA comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.
Int J Technol Assess Health Care
April 2012
Objectives: Pharmaceutical reimbursement agencies' processes and methods of appraisal vary across countries. The objective of this study was to examine the contribution of formal health economic analysis in a process using such analysis in Scotland in comparison to a process not routinely using such analysis in France.
Methods: A framework for classifying reimbursement systems was used to analyze the two systems.